Start Date
Immediate
Expiry Date
07 Dec, 25
Salary
125000.0
Posted On
09 Sep, 25
Experience
1 year(s) or above
Remote Job
Yes
Telecommute
Yes
Sponsor Visa
No
Skills
Data Analysis, Assay Development, Cell Lines, Tissue Culture, Biology, Molecular Biology, Graphpad Prism, Flow Cytometry, Microsoft Office, Communication Skills, Software, Bioengineering, Management Skills, Cell Biology, Primary Cells
Industry
Pharmaceuticals
Job Description: Staff Scientist I, Discovery Biology
The Discovery Biology team at Protagonist Therapeutics is seeking a highly motivated Staff Scientist for a full-time research laboratory position. The individual is expected to perform a variety of diverse laboratory activities, including assay development (cell-based assays), biomarker identification, quantification, and interpretation (PD, efficacy), as well as understanding of structure-activity relationships (SAR). They are also expected to possess excellent verbal and written communication skills. This role requires working collaboratively within the team structure (departmental and program team) to support multiple research programs from preclinical discovery to clinical development.
Key responsibilities:
Qualifications:
The base pay range for this position at commencement of employment is expected to be between $118K and $125K / year; however, base pay offered may vary depending on multiple individualized factors, including market location, job-related knowledge, skills, and experience.
Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides, icotrokinra and rusfertide, derived from Protagonist’s proprietary discovery platform are currently in advanced Phase 3 clinical development, with New Drug Application submissions to the FDA expected in 2025. Icotrokinra (JNJ-2113) is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor ("IL-23R") which is licensed to Janssen Biotech, Inc., a Johnson & Johnson company. Following icotrokinra’s joint discovery by Protagonist and Johnson & Johnson scientists pursuant to the companies’ IL-23R collaboration, Protagonist was primarily responsible for development of icotrokinra through Phase 1, with Johnson & Johnson assuming responsibility for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural hormone hepcidin, is currently in Phase 3 development for the rare blood disorder polycythemia vera (PV). Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered into in 2024 under which the Company remains primarily responsible for development through NDA filing. The Company also has a number of pre-clinical stage oral drug discovery programs addressing clinically and commercially validated targets, including the IL-17 oral peptide antagonist PN-881, an oral hepcidin program, and an oral obesity program.
How To Apply:
Incase you would like to apply to this job directly from the source, please click here